Effects of 12-Week Supplementation of a Polyherbal Formulation in Old Adults with Prehypertension/Hypertension: A Randomized, Double-Blind, Placebo-Controlled Trial

Table 2

Demographics and medical history of the participants.

Items	Male			Female			Total
	HyperBalance	Placebo	Combined	HyperBalance	Placebo	Combined	HyperBalance	Placebo	Combined
Gender, N (% of subtotal)	14 (29.8)	17 (33.3)	31 (31.6)	33 (70.2)	34 (66.7)	67(68.4)	50 (100)	48 (100)	98 (100)
Age, year (mean ± s.d)	65.35 ± 7.12	67.18 ±7.4	66.41 ± 7.25	64.79 ± 7.29	63.67 ± 6.53	64.31 ± 6.94	64.97 ± 7.17	65.28 ± 7.09	65.12 ± 7.10
Age, year (range)	52.87-82.80	47.28-83.47	52.87-84.46	53.18-84.86	49.03-88.43	47.28-88.43	52.87-84.86	47.28-88.43	47.28-88.43
Smoking (Yes/Total, %)	8/50 (16.0)	5/48 (10.5)	13/98 (13.3)	0(0)	0(0)	0(0)	8/50 (16.0)	5/48 (10.5)	13/98 (13.3)
Alcohol drinking (Y/T, %)	6/50 (12.0)	5/48(10.5)	11/98(11.2)	0(0)	0(0)	0(0)	6/50 (12.0)	5/48 (10.5)	11/98 (11.2)
Hyperlipidemia (Y/T, %)	1/50 (2.0)	0(0)	1/98(1.0)	2/50(4.0)	3/48 (6.25)	5/98(5.1)	3/50 (6.0)	3/48 (6.25)	6/98 (6.12)
Prehypertension (Y/T, %)	12/50 (24)	18/48 (37.5)	30/98 (30.6)	29/50 (58)	22/48 (45.8)	51/98 (52.1)	41/50(82)	40/48(83.3)	81/98 (82.7)
Hypertension (Y/T, %)	3/50 (6)	4/48 (8.3)	7/98 (7.1)	6/50 (12)	4/48 (8.3)	10/98 (10.2)	9/50(18)	8/48(16.7)	17/98 (17.3)
History of anti-hypertension	12/50 (30.8)	20/48(47.6)	32/98(39.5)	27/50(69.2)	22/48(52.4)	49/98(60.5)	39/50 (78)	42/48 (87.5)	81/ 98 (82.7)
Medication (Y/T, %)